HeartSciences ROA 2022-2025 | HSCS
Current and historical return on assets (ROA) values for HeartSciences (HSCS) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| HeartSciences ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2025-01-31 | $-0.01B | $0.01B | -112.50% |
| 2024-10-31 | $-0.01B | $0.01B | -86.49% |
| 2024-07-31 | $-0.01B | $0.01B | -103.23% |
| 2024-04-30 | $-0.01B | $0.01B | -107.69% |
| 2024-01-31 | $-0.01B | $0.01B | -147.37% |
| 2023-10-31 | $-0.01B | $0.00B | -218.18% |
| 2023-07-31 | $-0.01B | $0.00B | -171.43% |
| 2023-04-30 | $-0.01B | $0.00B | -164.71% |
| 2023-01-31 | $-0.01B | $0.00B | -175.00% |
| 2022-10-31 | $-0.01B | $0.01B | -215.38% |
| 2022-07-31 | $-0.01B | $0.01B | -300.00% |
| 2022-04-30 | $-0.01B | $0.00B | -1000.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.004B | $0.000B |
| Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $46.136B | 58.95 |
| Hims & Hers Health (HIMS) | United States | $12.000B | 124.67 |
| Tempus AI (TEM) | United States | $10.868B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $4.592B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $4.068B | 63.55 |
| Hinge Health (HNGE) | United States | $3.121B | 0.00 |
| Privia Health (PRVA) | United States | $2.805B | 191.75 |
| Enovis (ENOV) | United States | $1.818B | 10.14 |
| Schrodinger (SDGR) | United States | $1.741B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.567B | 0.00 |
| Phreesia (PHR) | United States | $1.501B | 0.00 |
| Omnicell (OMCL) | United States | $1.466B | 25.86 |
| Azenta (AZTA) | United States | $1.310B | 60.89 |
| 10x Genomics (TXG) | United States | $1.150B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.648B | 0.00 |
| Claritev (CTEV) | United States | $0.605B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.591B | 0.00 |
| Talkspace (TALK) | United States | $0.553B | 165.25 |
| Veradigm (MDRX) | United States | $0.466B | 0.00 |
| Standard BioTools (LAB) | United States | $0.410B | 0.00 |
| TruBridge (TBRG) | United States | $0.353B | 784.00 |
| Outset Medical (OM) | United States | $0.342B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.275B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.263B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.200B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.130B | 0.00 |
| Pulmonx (LUNG) | United States | $0.124B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.118B | 0.00 |
| American Well (AMWL) | United States | $0.108B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.101B | 0.00 |
| CareCloud (CCLD) | United States | $0.091B | 3.45 |
| 111 (YI) | China | $0.071B | 0.00 |
| HeartBeam (BEAT) | United States | $0.057B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.047B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.035B | 0.00 |
| Zhongchao (ZCMD) | China | $0.028B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.026B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.022B | 0.00 |
| Precipio (PRPO) | United States | $0.016B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.016B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.012B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.010B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.009B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.000B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |